Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In American Oriental Bioengineering Inc. To Contact The Firm Regarding The August 22, 2012 Lead Plaintiff Deadline
Date:8/10/2012

NEW YORK, Aug. 10, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at American Oriental Bioengineering Inc. ("AOBI" or the "Company") (OTC Markets: AOBI).

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) certain of the Company's capsule products maintained chrome levels far exceeding humanly tolerable limits; (2) the Company's financial statements contained material inconsistencies; (3) the Company's internal controls over financial reporting were deficient; and (4), as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On March 16, 2012, the Company's independent registered public accounting firm, Ernst & Young Hua Ming ("E&Y"), informed AOBI's Audit Committee of inconsistencies in the Company's financial statements for fiscal year 2011.  Approximately one month later, on April 19, 2012, the Company disclosed "onsite short notice inspections" conducted by the Chinese State Food and Drug Administration at four of AOBI's five manufacturing subsidiaries after capsule products were discovered with chrome levels far exceeding humanly tolerable limits. Then, after being delisted by the New York Stock Exchange on May 25, 2012, the Company's common stock plummeted nearly 62% when it resumed trading over-the-counter on May 29, 2012.

On June 15, 2012, the Company disclosed that E&Y had withdrawn its audit reports for the Company's financial statements for the years ended 2009 and 2010, after E&Y concluded that it could no longer rely on management's representations in connection with its audits of the financial statements for those years.

Request more information now by clicking here:  www.faruqilaw.com/AOBI. There is no cost or obligation to you.

Take Action
If you purchased AOBI securities between November 9, 2009 and June 15, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/AOBI.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding AOBI's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com 
Francis McConville, Esq.
fmcconville@faruqilaw.com 
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
2. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
3. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. The Future of R&D Outsourcing
6. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
7. Searcy Denney Scarola Barnhart & Shipley PA Seeks Damages Caused by Recalled Product
8. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
9. Positron Consolidates Radiopharmaceutical & Radioisotope Facilities
10. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
11. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology:
(Date:4/21/2017)... Utah (PRWEB) , ... April 21, 2017 , ... ... wilderness therapy treatment for adolescents and young adults, has kicked off its 4th ... April 23rd. This year’s theme is “Attachment Informed Therapy for Mental Health ...
(Date:4/21/2017)... ... 21, 2017 , ... The Patient Advocacy Community of The Beryl Institute presented ... Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the ... award at The Beryl Institute’s annual Patient Experience Conference on March 20 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... ... Providing for loved ones before one’s passing is of paramount importance. However, ... “Now more than ever there are some questions that are far too critical to ... attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
(Date:4/21/2017)... ... ... During April 21-23, Super-Sod will join the vendor market of the Sacred ... — from the avid gardener to the landscape admirer — during the three-day schedule. ... a grand venue, and we are certainly looking forward to participating in this year’s ...
Breaking Medicine News(10 mins):